ROYALTY PHARMA

Press Release
November 25, 2026

Royalty Pharma to present at upcoming investor conferences

NEW YORK, NY, November 25, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December:

- Evercore's 9th Annual Healthcare Conference on Tuesday, December 1, 2026 at 2:10 p.m. ET
- Citi's 2026 Global Healthcare Conference on Wednesday, December 2, 2026 at 1:00 p.m. ET

The webcasts will be accessible from Royalty Pharma's "Events" page at https://www.royaltypharma.com/investors/events/. Webcasts will also be archived for a minimum of thirty days.

About Royalty Pharma plc

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma's current portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta and Alyftrek, GSK's Trelegy, Biogen's Tysabri and Spinraza, Roche's Evrysdi, Astellas and Pfizer's Xtandi, Johnson & Johnson's Tremfya, AbbVie and Johnson & Johnson's Imbruvica, Servier's Voranigo, Gilead's Trodelvy, Amgen's Imdelltra and Alnylam's Amvuttra, among others, and 16 development-stage product candidates. For more information, visit https://www.royaltypharma.com/.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com